Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 1,161 shares, a growth of 57,950.0% from the June 30th total of 2 shares. Based on an average daily volume of 3,040 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the shares of the company are sold short.
Enzon Pharmaceuticals Stock Performance
Shares of OTCMKTS:ENZN remained flat at $4.35 on Friday. 2,271 shares of the company’s stock were exchanged, compared to its average volume of 1,513. The company’s fifty day moving average price is $5.22 and its two-hundred day moving average price is $5.72. Enzon Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $9.50. The firm has a market cap of $3.22 million, a P/E ratio of -0.64 and a beta of -0.05. The company has a quick ratio of 1.16, a current ratio of 2.01 and a debt-to-equity ratio of 0.42.
Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) last announced its earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The firm had revenue of $86.54 million for the quarter.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Recommended Stories
- Five stocks we like better than Enzon Pharmaceuticals
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
